Something Grim Is Happening to People Who Go Off GLP-1s

Patients who stop GLP-1 therapies such as Ozempic, Wegovy and Mounjaro commonly regain much of their lost weight—research cited by Novo Nordisk indicates patients typically regain about two‑thirds of lost weight, with clinicians observing 60–80% regain—prompting high-profile users like Oprah to announce plans for indefinite use. The persistence of appetite rebound implies obesity may be managed as a chronic condition, supporting recurring revenue streams for manufacturers (Novo Nordisk, Eli Lilly) but also creating potential reputational and adherence risks; some patients can sustain losses if they adopt lasting lifestyle changes while on therapy.

Analysis

Market structure: Chronic dependence implied by weight rebound materially increases lifetime revenue per patient for leading GLP-1 makers (Novo Nordisk NVO, Eli Lilly LLY). Near-term winners: large-cap manufacturers, contract manufacturers, injector device suppliers and specialized clinics that partner with pharma; losers: consumer diet brands (WW), certain bariatric services and OTC weight-loss retail. Expect constrained supply vs demand for 6–12 months, supporting pricing power but inviting payer scrutiny.

Risk assessment: Tail risks include class-wide safety signals, rapid payer coverage restrictions (CMS/private insurers), or manufacturing failures that could cut sales >30% in weeks. Immediate (days-weeks): sentiment swings/black-market stories; short-term (1–6 months): quarterly sales/production updates and reimbursement decisions; long-term (1–5 years): chronic therapy adoption vs competition (oral GLP-1s, biosimilars). Hidden dependency: durable demand depends on insurance coverage and affordability — a 20–40% copay shift could materially reduce persistence.

Trade implications: Favor NVO-led exposure sized 2–3% of portfolio funded from consumer-diet/retail shorts. Use options to cap downside: buy 12-month call spread (buy 10% OTM, sell 30% OTM) sized 1–2% capital, and hedge with 6–9 month puts at 5–10% OTM sized to 25% of long delta. Pair trade: long NVO (1.5%) / short WW (0.75%) for 6–12 months; exit on reimbursement restriction or +30% equity move.

Contrarian angles: Consensus overlooks rapid payer pushback risk — upside may be overstated in near term while medium-term fundamentals remain strong if chronic use persists. Historical parallel: HCV cures saw heavy initial pricing scrutiny but sustained high-margin revenues for incumbents; mispricings exist where small-cap suppliers of ancillary services are priced as beneficiaries but may lose share if pharma vertically integrates. Monitor three catalysts in 30–90 days: CMS coverage guidance, NVO/LLY production updates, and any FDA safety advisories.

Key Decisions for Investors

• Establish a 2–3% long position in NVO within 2–6 weeks (ahead of next quarterly report) to capture chronic-use revenue growth; trim on a +25–35% move or if CMS issues restrictive coverage guidance.
• Deploy a 12-month call spread on NVO sized 1–2% capital: buy 12-month call ~10% OTM and sell 12-month call ~30% OTM to express bullish view with capped cost; close on either +50% spread gain or regulatory/payer adverse headline.
• Initiate a pair trade: long NVO 1.5% vs short WW (WeightWatchers) 0.75% equal-dollar for 6–12 months — thesis: durable pharma revenue vs secular decline for consumer diet brands; unwind if WW outperforms by 20% or NVO misses consensus by >10%.
• Hedge downside: buy 6–9 month puts on NVO ~5–10% OTM sized to 25% of long position cost to protect against rapid regulatory or safety-driven drawdowns.
• Monitor and act on three near-term catalysts (30–90 days): CMS/private payer coverage statements, NVO/LLY monthly production capacity updates, and any FDA safety communications — reduce exposure by 50% if any single catalyst signals material negative (e.g., payer restricts reimbursement to <30% of patient population).